Glass House Brands (GLAS) Net Income towards Common Stockholders (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Net Income towards Common Stockholders of -$14.1 million for Q1 2026, down 828.48% year-over-year from $1.9 million in Q1 2025, and up 8.92% quarter-over-quarter from -$15.5 million in Q4 2025.
Glass House Brands (GLAS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$14.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 828.48% year-over-year to -$14.1 million; the TTM figure through Mar 2026 stood at -$29.3 million (down 285.13% YoY), while the FY2025 annual figure was -$29.0 million, down 4115.53% from the prior year.
- Net Income towards Common Stockholders climbed to -$14.1 million in Q1 2026 per GLAS's latest filing, from -$15.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $15.2 million in Q3 2022 and bottomed at -$19659.4 billion in Q2 2023.
- Historically, Net Income towards Common Stockholders has averaged -$2007.4 billion across 5 years, with a median of -$12.2 million in 2025.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 809.89% — and 2026, when it plunged 828.48%.
- Glass House Brands' Net Income towards Common Stockholders stood at -$29.6 million in 2022, then plunged by 44.13% to -$42.6 million in 2023, then jumped by 104.55% to $1.9 million in 2024, then sank by 899.79% to -$15.5 million in 2025, then rose by 8.92% to -$14.1 million in 2026.
- Business Quant data shows GLAS's Net Income towards Common Stockholders at -$14.1 million in Q1 2026, -$15.5 million in Q4 2025, and -$10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Glass House Brands | 840.76 Mn | 822.21 Mn | 15.77 Mn | -3.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.12 Mn |
| Dec 31, 2025 | -15.50 Mn |
| Sep 30, 2025 | -10.25 Mn |
| Jun 30, 2025 | 10.61 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 11.93 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | -42.60 Mn |
| Sep 30, 2023 | -273,000.00 |
| Jun 30, 2023 | -19,659.40 Bn |
| Mar 31, 2023 | -31.04 Mn |
| Dec 31, 2022 | -29.55 Mn |
| Sep 30, 2022 | 15.18 Mn |
| Jun 30, 2022 | -12,459.45 Bn |
| Mar 31, 2022 | -21.28 Mn |
| Dec 31, 2021 | -22.46 Mn |
| Sep 30, 2021 | -6,955.68 Bn |
| Jun 30, 2021 | -13,606.55 Bn |
| Mar 31, 2021 | -13.15 Mn |